Role for polyamines in Ebola Virus Replication

多胺在埃博拉病毒复制中的作用

基本信息

  • 批准号:
    9018817
  • 负责人:
  • 金额:
    $ 24.63万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-02-01 至 2018-01-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): The Filoviridae are a small family of viruses that include the highly pathogenic Ebola and Marburg viruses. These viruses are associated with fatality rates of up to 90%. As has been highlighted during the recent outbreaks of Ebola in Western Africa, filoviruses have tremendous potential for adverse health effects both directly (through direct pathogenesis) and indirectly (forcing the shutdown of existing clinics and treatment programs, sparking panic). Though a variety of potential therapies for the disease have been developed and deployed, it is currently unclear which if any have helped. A clear lesson from the outbreak is that the lack of basic information about viruses like Ebola have hampered effective control and therapy. In this vein, it is clear that basic aspects of how Ebola and its relatives utilize components of infected cells to their advantage are still unknown. A detailed understanding of how Ebola "steals" from its host or identification of cellular processes that the virus requires can offer important insight into both the general biology of the virus and can lead to the identification of host processes that can be effectively targeted to block viral replication. This proposal will test the hypothesis that polyamines and products of polyamines such as the non-canonical amino acid hypusine are essential for Ebola virus replication. To test this hypothesis we will use existing small- molecules that target the polyamine synthesis pathway and we will use gene-targeting knockdown technology to assess the importance of polyamine synthesis enzymes, hypusination enzymes and the hypusinated protein eIF5A on Ebola virus gene expression. Through these studies we hope to determine the importance of this pathway for viral gene expression and understand the mechanism by which the polyamine pathway controls viral gene expression. Identification of this pathway as important for Ebola virus replication has significant translational implications, as there are many compounds that are known to target the polyamine and hypusine synthesis pathways. Some of these are FDA-approved, some are in advanced development. Data supporting our hypothesis that this pathway is important can lead to the testing of these compounds in animal models of disease.
 描述(由申请方提供):丝状病毒科是一个病毒小家族,包括高致病性埃博拉病毒和马尔堡病毒。这些病毒的致死率高达90%。正如最近在西非爆发的埃博拉疫情所强调的那样,丝状病毒具有直接(通过直接发病机制)和间接(迫使现有诊所和治疗计划关闭,引发恐慌)对健康产生不利影响的巨大潜力。虽然已经开发和部署了各种潜在的治疗方法,但目前还不清楚是否有任何帮助。从疫情中得到的一个明确教训是,缺乏有关埃博拉病毒等病毒的基本信息阻碍了有效的控制和治疗。在这种情况下,很明显,埃博拉病毒及其亲属如何利用受感染细胞的成分对其有利的基本方面仍然是未知的。详细了解埃博拉病毒如何从其宿主“窃取”或确定病毒所需的细胞过程可以提供对病毒的一般生物学的重要见解,并可以导致确定可以有效靶向阻断病毒复制的宿主过程。该提案将检验多胺和多胺产物(如非规范氨基酸羟腐胺赖氨酸)对埃博拉病毒复制至关重要的假设。为了检验这一假设,我们将使用靶向多胺合成途径的现有小分子,并且我们将使用基因靶向敲低技术来评估多胺合成酶、羟腐胺赖氨酸化酶和羟腐胺赖氨酸化蛋白eIF5A对埃博拉病毒基因表达的重要性。通过这些研究,我们希望确定该途径对病毒基因表达的重要性,并了解多胺途径控制病毒基因表达的机制。鉴定该途径对埃博拉病毒复制的重要性具有重要的翻译意义,因为已知有许多化合物靶向多胺和羟腐胺赖氨酸合成途径。其中一些是FDA批准的,一些是在先进的发展。数据支持我们的假设,这一途径是重要的,可以导致这些化合物在动物模型中的疾病的测试。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

John H Connor其他文献

John H Connor的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('John H Connor', 18)}}的其他基金

Advancement of poxvirus inhibitor
痘病毒抑制剂的研究进展
  • 批准号:
    10576934
  • 财政年份:
    2020
  • 资助金额:
    $ 24.63万
  • 项目类别:
Advancement of poxvirus inhibitor
痘病毒抑制剂的研究进展
  • 批准号:
    10381584
  • 财政年份:
    2020
  • 资助金额:
    $ 24.63万
  • 项目类别:
Stage-Specific Inhibitors of Orthopoxviruses
正痘病毒阶段特异性抑制剂
  • 批准号:
    8136883
  • 财政年份:
    2011
  • 资助金额:
    $ 24.63万
  • 项目类别:
Development of Near Real-Time, Multiplexed Diagnostics for Viral Hemorrhagic Feve
病毒性出血热近实时多重诊断的开发
  • 批准号:
    8511558
  • 财政年份:
    2011
  • 资助金额:
    $ 24.63万
  • 项目类别:
Stage-Specific Inhibitors of Orthopoxviruses
正痘病毒阶段特异性抑制剂
  • 批准号:
    8257919
  • 财政年份:
    2011
  • 资助金额:
    $ 24.63万
  • 项目类别:
Development of Near Real-Time, Multiplexed Diagnostics for Viral Hemorrhagic Feve
病毒性出血热近实时多重诊断的开发
  • 批准号:
    8302193
  • 财政年份:
    2011
  • 资助金额:
    $ 24.63万
  • 项目类别:
Development of Near Real-Time, Multiplexed Diagnostics for Viral Hemorrhagic Feve
病毒性出血热近实时多重诊断的开发
  • 批准号:
    8711239
  • 财政年份:
    2011
  • 资助金额:
    $ 24.63万
  • 项目类别:
Development of Near Real-Time, Multiplexed Diagnostics for Viral Hemorrhagic Feve
病毒性出血热近实时多重诊断的开发
  • 批准号:
    8184838
  • 财政年份:
    2011
  • 资助金额:
    $ 24.63万
  • 项目类别:
New Ops-Proof of Concept Studies on a Class of Broad Spectrum Antiviral Compounds
一类广谱抗病毒化合物的新操作概念验证研究
  • 批准号:
    7942397
  • 财政年份:
    2009
  • 资助金额:
    $ 24.63万
  • 项目类别:
New Ops: Proof of concept studies on a class of broad spectrum antiviral compound
新行动:一类广谱抗病毒化合物的概念验证研究
  • 批准号:
    7645451
  • 财政年份:
    2008
  • 资助金额:
    $ 24.63万
  • 项目类别:

相似海外基金

ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
  • 批准号:
    10935820
  • 财政年份:
    2023
  • 资助金额:
    $ 24.63万
  • 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
  • 批准号:
    10932514
  • 财政年份:
    2023
  • 资助金额:
    $ 24.63万
  • 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
  • 批准号:
    10704845
  • 财政年份:
    2023
  • 资助金额:
    $ 24.63万
  • 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
  • 批准号:
    10709085
  • 财政年份:
    2023
  • 资助金额:
    $ 24.63万
  • 项目类别:
Advanced Development of Gemini-DHAP
Gemini-DHAP的高级开发
  • 批准号:
    10760050
  • 财政年份:
    2023
  • 资助金额:
    $ 24.63万
  • 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
  • 批准号:
    10409385
  • 财政年份:
    2022
  • 资助金额:
    $ 24.63万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
  • 批准号:
    10710595
  • 财政年份:
    2022
  • 资助金额:
    $ 24.63万
  • 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
  • 批准号:
    10630975
  • 财政年份:
    2022
  • 资助金额:
    $ 24.63万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
  • 批准号:
    10710588
  • 财政年份:
    2022
  • 资助金额:
    $ 24.63万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
  • 批准号:
    10788051
  • 财政年份:
    2022
  • 资助金额:
    $ 24.63万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了